

Identification of the In Vivo Role of a Viral *bcl-2*

Shivaprakash Gangappa,¹ Linda E. van Dyk,¹ Travis J. Jewett,²
Samuel H. Speck,³ and Herbert W. Virgin IV^{1,2}

¹Department of Pathology and Immunology, and ²Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110

³Division of Microbiology and Immunology, Yerkes Regional Primate Research Center, Emory University, Atlanta, GA 30329

Abstract

Many γ -herpesviruses encode candidate oncogenes including homologues of host *bcl-2* and cyclin proteins (*v-bcl-2*, *v-cyclin*), but the physiologic roles of these genes during infection are not known. We show for the first time in any virus system the physiologic role of *v-bcl-2*. A γ -herpesvirus *v-bcl-2* was essential for efficient ex vivo reactivation from latent infection, and for both persistent replication and virulence during chronic infection of immunocompromised (interferon [IFN]- $\gamma^{-/-}$) mice. The *v-cyclin* was also critical for the same stages in pathogenesis. Strikingly, while the *v-bcl-2* and *v-cyclin* were important for chronic infection, these genes were not essential for viral replication in cell culture, viral replication during acute infection in vivo, establishment of latent infection, or virulence during acute infection. We conclude that *v-bcl-2* and *v-cyclin* have important roles during latent and persistent γ -herpesvirus infection and that herpesviruses encode genes with specific roles during chronic infection and disease, but not acute infection and disease. As γ -herpesviruses primarily cause human disease during chronic infection, these chronic disease genes may be important targets for therapeutic intervention.

Key words: viral genes • viral latency • reactivation • persistent replication • chronic infection

Introduction

Regulation of both cell cycle progression and apoptosis is critical for many aspects of virus infection, particularly for oncogenic DNA viruses such as adenoviruses, polyomaviruses, papillomaviruses, and γ -herpesviruses. Adenoviruses, polyomaviruses, and papillomaviruses target the functions of pRb and p53 to regulate cellular functions such as cell cycle and apoptosis with significant consequences including oncogenesis (1–4). Oncogenic γ -herpesviruses manipulate the same aspects of cell function via expression of multiple genes including *v-bcl-2* and *v-cyclin*. While these genes clearly regulate important aspects of cellular physiology, the physiologic role of these genes during infection is unknown.

v-bcl-2 genes are encoded by oncogenic γ -herpesviruses including the human γ -herpesviruses EBV and Kaposi's sarcoma herpesvirus (KSHV),* the primate γ -herpesvirus

herpesvirus saimiri (HVS), and the closely related murine virus γ -herpesvirus 68 (γ HV68) (5–10). Adenovirus and African swine fever virus also encode anti-apoptotic *v-bcl-2* proteins (11–16). The in vivo role of *v-bcl-2* genes has never been defined. However, the capacity of these proteins to inhibit apoptosis is clear since transient expression of γ -herpesvirus *v-bcl-2* proteins is anti-apoptotic for cells in culture (6–10). An EBV *v-bcl-2* mutant has been constructed, but had no detectable phenotype in immortalization of primary human B cells (17). This lack of phenotype suggests that the *v-bcl-2* gene may play a role in infection that can only be detected by in vivo experimentation.

Consistent with a role for regulation of cell cycle progression in γ -herpesvirus infection and disease, KSHV, HVS, and γ HV68 encode a *v-cyclin*, and EBV regulates the expression of host cyclin molecules (5, 18–25). To determine the in vivo role for *v-cyclin* we characterized γ HV68 *v-cyclin* mutants. We found that the γ HV68 *v-cyclin* is onco-

Address correspondence to H.W. Virgin, Department of Pathology and Immunology, Washington University School of Medicine, Box 8118, 660 South Euclid Ave., Phone: 314-362-9223; Fax: 314-362-4096; E-mail: virgin@immunology.wustl.edu or S.H. Speck, Division of Microbiology and Immunology, Yerkes Regional Primate Research Center, Emory University, Atlanta, GA 30329. Phone: 404-727-7665; Fax: 404-727-7768; E-mail: speck@rmy.emory.edu

*Abbreviations used in this paper: CPE, cytopathic effect; γ HV68, γ -her-

pesvirus 68; HVS, herpesvirus saimiri; KSHV, Kaposi's sarcoma herpesvirus; MEF, mouse embryonic fibroblast; RAG, recombination activating gene; wt, wild-type.

genic when expressed in transgenic mice (26), and is required for efficient ex vivo reactivation from viral latency, but not for viral replication in wild type mice during acute infection (18, 27). The role of the *v-cyclin* in persistent replication and chronic disease has not been assessed.

In this study we use loss of function mutagenesis to evaluate the role of the *v-bcl-2* gene in γ HV68 infection in vivo. Because regulation of cell cycle and apoptosis is intimately intertwined during infection with papillomaviruses, polyomaviruses, and adenoviruses, we compared properties of *v-bcl-2* and *v-cyclin* mutants. We found that neither of these genes has an important role during acute infection, but that both are important for ex vivo reactivation from latency, persistent replication, and disease during chronic infection.

Materials and Methods

Viruses and Tissue Culture. γ HV68 clone WUMS (ATCC VR1465) was passaged, grown, and titered in NIH 3T12 cells or BALB/c or C57Bl/6 murine embryonic fibroblasts (MEFs) as described (18, 28). Viral stocks were generated from NIH 3T12 cells infected at multiplicity of infection (MOI) = 0.05 and harvested at 50% cytopathic effect (CPE) (18).

Generation of Mutant γ HV68 by Homologous Recombination. The parental genomic subclone for the targeting plasmids contains the 3,723 bp BamHI/BsrGI fragment of γ HV68 from genomic coordinates 101,654 to 105,377 in Litmus 38 (pL3700; references 5 and 18). The pL3700-*v-bcl-2*.Stop1 mutant targeting plasmid was generated using PCR and primers that excise 70 bp (from 103,641 to 103,711) and insert the 9 bp, 5' CTCAG-TAG 3', which includes an XhoI site (underlined) and an in frame stop codon (bold). For pL3700-*v-bcl-2*.Stop2, the primers insert 7 bp, 5' AGCTAGC 3', which includes an NheI site (underlined) and a stop codon (bold) at genomic coordinate 103,450. The *v-bcl-2* mutant viruses were generated by transfection of NIH 3T12 cells with *v-cyclin*.LacZ virus genomic DNA (1.5 μ g) and pL3700-*v-bcl-2* mutant plasmid (1.5 μ g) (18, 29). Recombinant virus was purified by white plaque morphology after staining with X-Gal (5-bromo-4-chloro-3-indole- β -D-galactoside) (18). The *v-cyclin* marker rescue virus (*v-cyclin*.MR) has been described previously (18). Plaque purified (three rounds) viral stocks were characterized by Southern blot and Western blot analyses (18, 29).

Mice, Infections, and Organ Harvests. Recombination activating gene (RAG)-1^{-/-} (The Jackson Laboratory; 002096) and IFN- γ ^{-/-} mice (The Jackson Laboratory; 002287) on a C57Bl/6 background (B6) were bred and maintained at Washington University School of Medicine in accordance with all federal and university policies. C57Bl/6J (B6) mice were purchased from The Jackson Laboratory. γ interferon receptor-deficient (IFN γ R^{-/-}) mice on a 129 background were obtained from Michel Aguet, Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland (30). Unless otherwise stated, mice were age and sex matched, used between 7 to 10 wk of age, and infected with 10, 10³, or 10⁶ PFU of γ HV68 by intraperitoneal injection in 0.5 ml of complete DMEM (18, 29). CD-1 outbred lactating mice with pups (12 d old) were obtained from Charles River Laboratories, and the pups were infected intracerebrally with virus diluted in 10 μ l of complete DMEM. Organs for titer were frozen at -80°C in 1 ml DMEM before plaque assay (18,

29). Peritoneal cells were harvested by peritoneal lavage with 10 ml DMEM (31). To assess inflammatory disease in the great elastic arteries, the heart and attached aortic base were harvested at the time of death or sacrifice from IFN γ R^{-/-} mice and analyzed for incidence and severity of arteritic lesions (32, 33).

Quantitation of Cells Harboring γ HV68 Genome. The frequency of cells harboring the γ HV68 genome was determined by a limiting dilution nested PCR assay that amplifies γ HV68 gene 50 sequences with single copy sensitivity (31, 34). Briefly, peritoneal cells and splenocytes were frozen in 10% DMSO at -80°C, thawed, counted, resuspended in isotonic buffer, and serially diluted into 96-well PCR plates. Uninfected NIH 3T12 cells were added so that each well contained 10⁴ cells. Cells were then lysed in proteinase K and nested PCR performed (31, 34). 10 PCR reactions were analyzed for each cell dilution, with six dilutions per sample per experiment. Control reactions in each experiment included uninfected cells alone (6 reactions/plate) or cells with 10, 1, or 0.1 copies of plasmid DNA (pBam HIN) containing target sequence (six reactions/plate each). There were no false-positive PCR reactions in assays reported here, and all assays demonstrated approximately one-copy sensitivity for plasmid DNA, with reactions containing 10, 1, or 0.1 copies of plasmid DNA positive in 89, 29, and 3% of all reactions.

Ex Vivo Reactivation from Latency. The frequency of cells reactivating from latency ex vivo was determined using a limiting dilution reactivation assay (28, 34). Briefly, peritoneal cells and splenocytes were harvested 16, 28, or 42 d after infection, and plated in serial twofold dilution (starting at 4 \times 10⁴ peritoneal cells and 10⁵ splenocytes per well) onto MEF monolayers in 96-well plates. Wells were scored microscopically 21 d later for viral CPE. When CPE was difficult to discern at high cell numbers, wells were replated onto fresh MEFs and CPE assessed. 24 wells were plated per dilution and 12 dilutions were plated per sample. Preformed virus in tissues was detected by plating parallel cell samples that had been subjected to mechanical disruption. Mechanical disruption does not inactivate virus but kills >99% of cells, and thus samples treated in this way detect preformed virus rather than virus reactivating from latency (28, 31, 34).

Statistical Methods. All data was analyzed using GraphPad Prism software (GraphPad Software). Titer data were statistically analyzed with the nonparametric, Mann-Whitney *t* test. Frequencies were obtained from the cell number at which 63% of the wells scored positive for either reactivating virus or the presence of viral genome based on Poisson distribution. Data were subjected to nonlinear regression analysis to obtain single-cell frequency for each limiting dilution analysis. The frequencies of reactivation and genome-positive cells were statistically analyzed by paired *t* test. Alterations in the incidence of arteritis were compared using χ -square test and Fisher's exact test (which gave comparable results).

Results

Generation of Viruses Containing Mutations in the γ HV68 *v-bcl-2* Gene. To determine the role of *v-bcl-2* in viral infection, we constructed four γ HV68 *v-bcl-2* mutants. The γ HV68 *v-bcl-2* ORF (M11 original designation) spans 513 bp located between the *v-cyclin* gene (ORF72) and ORF73 (Fig. 1 A). Of the four recognized *bcl-2* homology domains (BH domains; BH1-BH4) that are conserved between different *bcl-2* family members, the predicted γ HV68-*v-bcl-2* protein has a recognizable BH1-like do-

main, but lacks clear BH2, BH3, or BH4 domains (5–7). The γ HV68 *v-bcl-2* also shares with *bcl-2* and *v-bcl-2* proteins a hydrophobic COOH-terminal domain (5–10). Presuming the functional importance of conserved regions of the protein, we constructed two γ HV68 mutants with stop codons and frame shift mutations in the *v-bcl-2* ORF (*v-bcl-2*.Stop1, *v-bcl-2*.Stop2) in which neither the BH1 domain nor the COOH-terminal hydrophobic domain should be translated (Fig. 1). The Stop1 mutation deletes the predicted BH1 domain and inserts a stop codon after 76

amino acids of the predicted 171 amino acid *v-bcl-2* (Fig. 1 B). *v-bcl-2*.Stop2 contains a mutation that inserts a stop codon and frame shift mutation after 10 amino acids of the *v-bcl-2* (Fig. 1 B). We generated two independent clones of each construct, indicated as A and B. The genomic structure of *v-bcl-2*.Stop1A and 1B, and *v-bcl-2*.Stop2A and 2B were confirmed by Southern blot analyses (Fig. 1 C). Western blot analysis showed that *v-bcl-2*.Stop viruses express *v-cyclin* normally in lytically infected 3T12 fibroblasts (Fig. 1 D).




Figure 1. Genomic structure of *v-bcl-2*.Stop mutant viruses. (A) Schematic representation of the region of the γ HV68 genome encoding the *v-bcl-2* gene (M11 ORF; genomic coordinates 103,418–103,930) (reference 5), the structure of *v-bcl-2* mutant viruses and the *v-bcl-2* region Southern blot probe (genomic coordinates 101,654–105,377) (reference 5). The shaded region within ORF72 in the *v-cyclin*.LacZ virus represents a LacZ cassette insertion between 102,704 bp and 103,179 bp (reference 18). The crosshatched region in the M11 ORF in *v-cyclin*.LacZ signifies the part of the M11 ORF deleted in *v-bcl-2*.Stop1. (B) Schematic representation of the *v-bcl-2* ORF showing the position of the conserved BH1 domain and the sites of Stop1 and Stop2 mutations in the *v-bcl-2* ORF. Shaded regions are the portions of the ORF predicted to be translated. (C) Southern analysis of wt γ HV68, *v-bcl-2*.Stop1 and Stop2 mutants, *v-cyclin*.LacZ, and *v-cyclin*.MR viruses. Purified genomic viral DNA (1 μ g) from the indicated viruses was digested with XhoI and BamHI (lanes 1–5) or NheI and BamHI (lanes 6–10) and Southern analysis performed with the *v-bcl-2* region probe (A; references 18 and 29). Expected fragment sizes for XhoI and BamHI digests: lane 1/wt γ HV68, 5.2 kb; lane 2/*v-cyclin*.LacZ mutant, 3.8 kb and 1.1 kb; lane 3/*v-bcl-2*.Stop1A mutant, 3.3 and 1.9 kb; lane 4/*v-bcl-2*.Stop1B mutant, 3.3 and 1.9 kb; lane 5/*v-cyclin*.MR, 5.2 kb. Expected fragment sizes for NheI and BamHI digests: lane 6/wt γ HV68, 5.2 kb; lane 7/*v-cyclin*.LacZ mutant, 3.8 kb and 1.5 kb; lane 8/*v-bcl-2*.Stop2A mutant, 3.5 and 1.7 kb; lane 9/*v-bcl-2*.Stop2B mutant, 3.5 and 1.7 kb; lane 10/*v-cyclin*.MR; 5.2 kb. (D) Immunoblot analysis of wt γ HV68, *v-bcl-2*.Stop1 and Stop2 mutants, *v-cyclin*.LacZ, or *v-cyclin*.MR virus infected NIH 3T12 cell lysates for *v-cyclin* and β -actin protein expression.

As *v-bcl-2*.Stop viruses were derived from the γ HV68 mutant *v-cyclin*.LacZ, we compared the mutant viruses to both wild-type γ HV68 (wt γ HV68) and *v-cyclin*.MR, a virus in which the *v-cyclin*.LacZ mutation has been rescued using wt viral sequences (18). To definitively map the phenotypes we report to the *v-bcl-2* gene, we characterized two independently generated viral mutants containing each of two different mutations in the *v-bcl-2* gene. The use of two independent isolates to map a phenotype to a herpesvirus gene is an accepted approach (35–37).

No Role for *v-bcl-2* in Acute Replication. We first tested whether the γ HV68 *v-bcl-2* was required for viral replication in cultured cells or in acutely infected wt B6 or immunocompromised IFN- $\gamma^{-/-}$ mice on the B6 background. As predicted from studies of an EBV *v-bcl-2* mutant (17), γ HV68 *v-bcl-2*.Stop1 and *v-bcl-2*.Stop2 grew normally in cultured cells under both single step and multi-step growth conditions (Fig. 2, A and B). *v-bcl-2* mutants also replicated as well as wt γ HV68 in the spleen and liver of wt B6 mice 4 or 9 d after infection as measured by plaque assay (Fig. 2 C, left panel). Similarly, growth of *v-bcl-2* mutants during acute infection of IFN- $\gamma^{-/-}$ was indistinguishable from growth of wt γ HV68 (Fig. 2 C, right panel). These data show that *v-bcl-2* is not essential for replication during acute infection in either wt B6 or immunocompromised IFN- $\gamma^{-/-}$ mice. We have previously demonstrated that the *v-cyclin* is not required for replication during acute infection of wild type mice (18). We confirmed this finding and additionally showed that the *v-cyclin*, similar to the *v-bcl-2*, is not essential for replication in IFN- $\gamma^{-/-}$ mice (Fig. 2 C, right panel). While a 1.8-fold difference in titer between the wt γ HV68 and *v-cyclin*.MR at day 9 in B6 mice, and a 2.4-fold difference between *v-cyclin*.MR and *v-cyclin*.

Stop at day 4 in IFN- $\gamma^{-/-}$ mice reached statistical difference for spleen, the biological significance of such small differences in titer are unclear and do not influence our conclusions regarding *v-bcl-2* mutants.

***v-bcl-2* Is Important for Ex Vivo Reactivation from Latency, but Not Establishment of Latency.** Given the lack of a role for *v-bcl-2* during acute infection, we turned our attention to parameters of chronic infection. We examined the role of *v-bcl-2* in establishment of latency (stable carriage of the viral genome in a cell without active replication) and ex vivo reactivation from latency. By 16 d after infection, infectious γ HV68 is cleared from the spleen and peritoneal cells of wt B6 mice and latency is established (18, 28, 29, 32, 34). The γ HV68 *v-bcl-2* is not required for establishment of latency since splenocytes (data not shown) and peritoneal cells harvested 16 or 42 d after infection of B6 mice with wt γ HV68, *v-cyclin*.MR, or *v-bcl-2*.Stop mutants contained equivalent frequencies of viral genome bearing cells (Fig. 3 A). Despite normal establishment of latency and absence of productive infection as shown by the disrupted samples in Fig. 3 B, *v-bcl-2*.Stop mutants reactivated 4–5-fold less efficiently than either wt γ HV68 or *v-cyclin*.MR virus in the peritoneal exudate cells (PECs) but not in the spleen (data not shown) both day 16 and day 42 after infection (Fig. 3 B). This viral phenotype is similar to *v-cyclin* mutants which also fail to efficiently reactivate from latency (18, 27), suggesting that regulation of both apoptosis and cell cycle is key to ex vivo reactivation from the latent state.

The γ HV68 *v-bcl-2* and *v-cyclin* Are Necessary for Persistent Replication of Virus in Immunocompromised Hosts. Persistent replication of γ -herpesviruses likely contributes to both disease in immunocompromised hosts and spread of






Figure 2. γ HV68 *v-bcl-2* mutant viruses grow like wt γ HV68 in cultured cells and during acute infection of mice. NIH 3T12 cells were infected with 5.0 (A) or 0.05 (B) PFU of virus per cell and viral titer determined at the times indicated. Data is pooled from two experiments (mean \pm SEM). (C) Viral titers in spleen and liver of B6 (left panel) and IFN- $\gamma^{-/-}$ (right panel) mice 4 and 9 d after intraperitoneal infection with 10^6 PFU of virus. Data is pooled from two separate experiments with five mice total per time point/experiment (mean \pm SEM). The virus titer in the spleen were statistically significant (*) as follows. For B6 mice, day 9 spleen; wt γ HV68 versus *v-cyclin*.MR, 1.8-fold difference, $P = 0.03$. For IFN- $\gamma^{-/-}$ mice, day 4 spleen; *v-cyclin*.MR versus *v-cyclin*.Stop, 2.4-fold difference, $P = 0.001$.

A Establishment of latency- C57Bl/6 mice



B Ex vivo reactivation from latency- C57Bl/6 mice



v-cyclin.MR were statistically significant as follows: *v-bcl-2.Stop1* versus wt γ HV68, $P = 0.006$; *v-bcl-2.Stop2* versus wt γ HV68, $P = 0.005$; *v-bcl-2.Stop1* versus *v-cyclin.MR*, $P = 0.013$; *v-bcl-2.Stop2* versus *v-cyclin.MR*, $P = 0.010$. At 42 d (A and B, right panels), the decreased frequencies of ex vivo reactivation of both *v-bcl-2.Stop* mutants compared with wt γ HV68 and *v-cyclin.MR* were statistically significant as follows: *v-bcl-2.Stop1* versus wt γ HV68, $P = 0.004$; *v-bcl-2.Stop2* versus wt γ HV68, $P = 0.005$; *v-bcl-2.Stop1* versus *v-cyclin.MR*, $P = 0.006$; *v-bcl-2.Stop2* versus *v-cyclin.MR*, $P = 0.009$.

the viruses between hosts. Consistent with prior reports (18, 29), we did not detect persistent replication of either wt γ HV68 or *v-bcl-2.Stop* viruses in the spleen (data not shown) or peritoneal cells of normal mice 16 and 42 d after infection (Fig. 3 B, open symbols). However, wt γ HV68 persistently replicates in peritoneal cells of IFN- $\gamma^{-/-}$ mice for at least 6 wk after infection (unpublished data), providing a model for determining whether the *v-bcl-2* has a role in persistent replication. One scenario is that persistent replication is due to reactivation from latency. Because γ HV68 *v-cyclin* mutants share with *v-bcl-2* mutants (above) the phenotype of decreased reactivation from latency despite normal establishment of latency (18), we analyzed *v-bcl-2* and *v-cyclin* mutants for their capacity to persistently replicate in IFN- $\gamma^{-/-}$ mice.

Consistent with findings in immunocompetent B6 mice (Fig. 3), *v-bcl-2.Stop1* and *v-bcl-2.Stop2* showed 4–5-fold decreased frequency of reactivation from peritoneal cells of IFN- $\gamma^{-/-}$ mice compared with wt γ HV68 and *v-cyclin.MR* virus (Fig. 4, left panels). This decrease in ex vivo reactivation was not due to a decrease in the number of cells carrying the viral genome because PECs from IFN- $\gamma^{-/-}$ mice infected with *v-cyclin.MR*, *v-bcl-2.Stop*, or *v-cyclin.Stop* mutant contained comparable frequency of genome positive cells (Fig. 4 D). The *v-cyclin* is also required for efficient ex vivo reactivation from latency in cells from IFN- $\gamma^{-/-}$ mice (Fig. 4, A–C, left panels).


Interestingly, neither *v-bcl-2.Stop* nor *v-cyclin.Stop* mutants showed significant persistent replication in IFN- $\gamma^{-/-}$ mice (Fig. 4, A–C, right panels). Persistent replica-

tion was detected for both wt γ HV68 and control virus *v-cyclin.MR*. These results demonstrated the requirement for both *v-bcl-2* and *v-cyclin* genes for persistent replication in immunocompromised hosts. This is in striking contrast to the lack of a role for these genes in acute replication in either wt or IFN- $\gamma^{-/-}$ mice (Fig. 2). This demonstrates that different viral genes are required for acute replication and persistent replication, strongly arguing that acute and persistent γ -herpesvirus replication are genetically distinct processes.


Requirement for v-bcl-2 and v-cyclin for Lethal Chronic Disease but Not Lethal Acute Disease. The data presented so far argues for a specific role of *v-bcl-2* and *v-cyclin* in chronic but not acute infection. If this distinction is physiologically important, these genes should be required for virulence in models of chronic disease but not for virulence during acute infection. Chronically infected IFN- $\gamma^{-/-}$ and IFN γ R $^{-/-}$ mice develop lethal persistent infection and severe large vessel vasculitis (32). The vasculitis is due to persistent replication in smooth muscle cells of the immunoprivileged media of the great elastic arteries (33). Consistent with the data above demonstrating a critical role for *v-cyclin* and *v-bcl-2* in persistent replication in IFN- $\gamma^{-/-}$ mice, *v-bcl-2* mutant and *v-cyclin* mutant viruses killed IFN γ R $^{-/-}$ mice less efficiently than wt virus during chronic infection (Fig. 5 A). Evaluation of pathology of arteritic lesions revealed significant change in incidence of lesions (*v-cyclin.MR* [14/19 = 74%] versus *v-bcl-2.Stop* [10/35 = 28%], $P = 0.0002$; *v-cyclin.MR* versus *v-cyclin.Stop* [7/20 = 35%], $P = 0.001$) but not in the severity of aortic lesions between

Figure 3. *v-bcl-2* mutants establish latency normally but fail to reactivate efficiently during ex vivo culture. B6 mice were infected with 10^6 PFU of virus and peritoneal cells were harvested at 16 or 42 d after infection for quantitation of the frequency of latently infected cells (A) and the frequency of cells reactivating from latency (B). Data represent results of two to five separate experiments using two independent mutant isolates (mean \pm SEM), with each experiment containing cells pooled from five mice. The difference in frequency of genome positive cells at day 16 and day 42 were not statistically significant between the wt γ HV68 versus *v-bcl-2.Stop1* and *v-cyclin.MR* versus *v-bcl-2.Stop2*. At 16 d (A and B, left panels), the decreased frequencies of ex vivo reactivation of both *v-bcl-2.Stop* mutants compared with wt γ HV68 and


A *Ex vivo* reactivation from latency and persistent replication - IFN γ ^{-/-} mice




B *Ex vivo* reactivation from latency and persistent replication - IFN γ ^{-/-} mice



C *Ex vivo* reactivation from latency and persistent replication- IFN γ ^{-/-} mice



D Establishment of latency- IFN γ ^{-/-} mice



mutant versus wt γ HV68, $P = 0.0008$, *v-bcl-2* mutant versus *v-cyclin.MR*, $P = 0.0003$, *v-cyclin* mutant versus wt γ HV68, $P = 0.0001$, *v-cyclin* mutant versus *v-cyclin.MR*, $P = 0.0001$; for day 42 persistent productive replication, *v-bcl-2* mutant versus wt γ HV68, $P = 0.027$, *v-bcl-2* mutant versus *v-cyclin.MR*, $P = 0.008$, *v-cyclin* mutant versus wt γ HV68, $P = 0.032$, *v-cyclin* mutant versus *v-cyclin.MR*, $P = 0.011$. The difference in frequency of genome positive cells at day 16 and day 42 were not statistically significant between the *v-cyclin.MR* versus *v-bcl-2.Stop1* and *v-cyclin.MR* versus *v-cyclin.Stop*.

the *v-cyclin.MR*, *v-bcl-2* mutant, and the *v-cyclin* mutant virus infected mice (data not shown).

We noted that the phenotype of *v-bcl-2* and *v-cyclin* deficient viruses during chronic infection of IFN γ ^{-/-} was in contrast to the lack of a phenotype for these viruses in growth during acute infection of normal and IFN γ ^{-/-}

mice (Fig. 2 C). We considered the hypothesis that data on acute infection using IFN γ ^{-/-} is not comparable to data on chronic infection from IFN γ R^{-/-} mice. However, the phenotypes of IFN γ ^{-/-} mice and IFN γ R^{-/-} are similar using a number of different routes of infection and doses of wt γ HV68 (32, 38). To determine if decreased virulence of

Figure 4. *v-bcl-2* and *v-cyclin* are critical for persistent replication of γ HV68 in IFN γ ^{-/-} mice. IFN γ ^{-/-} mice were infected with 10⁶ PFU of virus and peritoneal cells were harvested at 16, 28, or 42 d after infection for quantitation of frequency of cells reactivating virus (A–C, left panels), amount of persistent virus (A–C, right panels), and frequency of latently infected cells (D). Data represent results of two to three experiments (mean \pm SEM), with each experiment containing cells pooled from five mice. Since at day 42 time point, no significant difference between *v-cyclin.MR* and wt γ HV68 was observed, only *v-cyclin.MR* was checked for day 16 and day 28 time points along with two independent isolates of *v-bcl-2.Stop1* and *v-cyclin.Stop*. For day 42 experiments, *v-bcl-2* mutant infection included two experiments with *v-bcl-2.Stop1* and one experiment with *v-cyclin.Stop* and one experiment with *v-cyclin.LacZ* at day 42 time point. The decreased frequencies of *ex vivo* reactivation and persistent productive replication of both *v-bcl-2* mutant and *v-cyclin* mutant compared with wt γ HV68 and *v-cyclin.MR* were statistically significant as follows: day 16 *ex vivo* reactivation, *v-bcl-2.Stop1* versus *v-cyclin.MR*, $P = 0.007$; *v-cyclin.Stop* versus *v-cyclin.MR*, $P = 0.003$; for day 16 persistent productive replication, *v-bcl-2.Stop1* versus *v-cyclin.MR*, $P = 0.014$; *v-cyclin.Stop* versus *v-cyclin.MR*, $P = 0.011$, for day 28 *ex vivo* reactivation, *v-bcl-2.Stop1* versus *v-cyclin.MR*, $P = 0.0009$, *v-cyclin.Stop* versus *v-cyclin.MR*, $P = 0.0001$; for day 28 persistent productive replication, *v-bcl-2.Stop1* versus *v-cyclin.MR*, $P = 0.0326$, *v-cyclin.Stop* versus *v-cyclin.MR*, $P = 0.028$, and for day 42 *ex vivo* reactivation, *v-bcl-2*




Figure 5. *v-bcl-2* and *v-cyclin* are necessary for lethal chronic disease but not for lethal acute disease. (A) IFN γ R $^{-/-}$ mice were infected intraperitoneally with *v-cyclin.MR*, *v-bcl-2.Stop*, or *v-cyclin.Stop* mutant virus and observed for lethality over 90 d after infection. The increase in percent survival of mice infected with *v-bcl-2* mutant virus or *v-cyclin.Stop* mutant virus compared with *v-cyclin.MR* virus was statistically significant as follows: *v-bcl-2.Stop* versus *v-cyclin.MR*, $P = 0.0003$; *v-cyclin.Stop* versus *v-cyclin.MR*, $P = 0.012$. (B) Survival of RAG-1 $^{-/-}$ mice infected intraperitoneally with 10^6 , 10^3 , or 10 PFU of virus. Data are pooled from two experiments ($n =$ number of mice). (C and D) Survival of CD1 mice (3–4 wk old) infected intracerebrally with *v-cyclin.MR*, *v-bcl-2.Stop 1*, or *v-cyclin.Stop* virus and observed for lethality over 21 d after infection. Data represent 20–30 mice per point pooled from 2–3 independent experiments. $P =$ NS indicates that there is no statistical difference between the indicated groups.

v-bcl-2 and *v-cyclin* mutant viruses was specific to chronic disease, we tested mutant viruses in two additional models of virulence during acute infection. The virulence of wt γ HV68 and *v-bcl-2.Stop1* was comparable in RAG-1 $^{-/-}$ mice infected with 10, 10^3 , or 10^6 PFU (Fig. 5 B). We previously showed that *v-cyclin* mutant γ HV68 is not attenuated in this same model (18). γ HV68 also causes acute lethal meningitis when administered intracerebrally into weanling mice (39). The virulence of *v-cyclin* and *v-bcl-2* mutants in this lethal meningitis model was indistinguishable from that of wt γ HV68 (Fig. 5, C and D). Thus, the lack of virulence of *v-bcl-2* and *v-cyclin* mutant viruses during chronic disease was not seen in two different models of acute disease, further supporting our conclusion that *v-bcl-2* and *v-cyclin* are viral genes with a physiologically important and specific role during chronic infection.

Discussion

We show here for the first time that a γ -herpesvirus *v-bcl-2*, as previously shown for a *v-cyclin*, is necessary for efficient ex vivo reactivation from latency. The importance of both anti-apoptotic and cell cycle regulatory proteins in ex vivo reactivation from latency suggests that the reactivation process requires cell cycle progression and triggers host or cellular apoptotic pathways that serve to prevent reactivation unless the virus counters with anti-apoptotic molecules.

Of special importance for understanding how herpesviruses cause disease, we demonstrate for the first time that herpesviruses have genes (*v-bcl-2* and *v-cyclin*) that are important for persistent replication and chronic disease in an immunocompromised host, but not acute replication and acute disease. This identifies persistent replication as a process that is genetically distinct from replication during acute infection, and shows that genes important for persistent replication are key virulence determinants.

v-bcl-2 Is Required for Efficient Ex Vivo Reactivation from Latency. γ HV68 establishes latency in a number of cells types including macrophages, dendritic cells, and B cells (28, 31, 40, 41). We found that establishment of latency does not require *v-bcl-2*. In this respect, *v-bcl-2* is similar to other γ HV68 genes we have analyzed including the *v-cyclin* and *M1* (18, 29). However, the *v-bcl-2* mutation resulted in inefficient ex vivo reactivation of virus from latently infected cells. In this respect the *v-bcl-2* gene is similar to *v-cyclin*, but distinct from the *M1* locus since mutations in the *M1* locus enhance the efficiency of ex vivo reactivation (18, 29). Thus, γ HV68 contains genes that both enhance and inhibit ex vivo reactivation, suggesting that the balance between latency and ex vivo reactivation is under tight regulation by multiple viral genes. The importance of *v-bcl-2* for ex vivo reactivation from latency and persistent replication is consistent with our prior demonstration that the *v-bcl-2* gene is actively transcribed in latently infected tissues (42). It is possible that additional

phenotypes of *v-bcl-2* mutants may be identified using different route of infection.

Why are both *v-bcl-2* and *v-cyclin* important for efficient ex vivo reactivation from latency? We speculate that latently infected cells are in a resting G₀ state, and that the process of ex vivo reactivation requires the *v-cyclin* for induction of cell cycle progression. In this scenario, the *v-bcl-2* would prevent apoptosis induced either by expression of viral genes critical for ex vivo reactivation or by proapoptotic host genes that come into play during ex vivo reactivation. It is interesting that the KSHV *v-cyclin* can induce apoptosis in cells when overexpressed, and that this is blocked by coexpression of the KSHV *v-bcl-2* (43). Similarly, the γ HV68 *v-cyclin* induces cell cycle progression in transgenic thymocytes and is oncogenic, despite causing increased apoptosis (26). Thus, the *v-bcl-2* may be needed to prevent an apoptotic response caused by *v-cyclin* expression.

It is also possible that the *v-bcl-2* prevents apoptosis induced by host proteins. For example, the γ HV68 and HVS *v-bcl-2* can block both Fas and TNF- α mediated apoptosis when over-expressed (6, 44), and the EBV *v-bcl-2* can inhibit granzyme-mediated apoptosis (45). This latter is particularly significant since deficiency of perforin (which is key for induction of apoptosis by host granzymes) results in increased number of latently infected cells (unpublished data). It will be important to determine the precise host and viral pathways for apoptosis induction that are inhibited by *v-bcl-2* expression from the viral genome, as opposed to overexpression in cultured cells. It is possible that the *v-bcl-2* is critical for blocking apoptosis induced by both host and viral proteins. Identification of apoptotic pathways inhibited by *v-bcl-2* may lead to therapies for γ -herpesvirus associated diseases, as enhancement of such pathways, for example by ablating *v-bcl-2* function, may prevent viral reactivation or inhibit persistent replication.

Different Genetic Requirements for Acute and Persistent Replication In Vivo. The demonstration that both the *v-bcl-2* and the *v-cyclin* are critical for persistent replication in an immunocompromised host, but not for acute infection, identifies persistent infection as a genetically distinct phase of herpesvirus infection in vivo. Thus, γ -herpesvirus infection in vivo has the following experimentally distinguishable components: acute replication, establishment of latency, maintenance of latency, persistent replication, and reactivation from latency. The presence of conserved genes with a specialized function during persistent replication rather than replication during acute infection suggests that persistent replication is a physiologically important component of herpesvirus infection.

It is likely that persistent replication contributes to spread of the virus within the population. In addition, it has been suggested that persistent replication may contribute to tumorigenesis by γ -herpesviruses (46). It is therefore possible that genes of the virus that are necessary for persistent replication will also contribute to tumorigenesis even if they are not independently oncogenic. This hypothesis predicts that induction of tumors by γ -herpesviruses could be prevented by targeting the function of genes essential for persistent

replication, even when the genes have no role in replication in tissue culture, replication during acute infection, or detectable transforming activity. It is important to note that there is no direct evidence to date that persistent replication occurs in normal hosts. However, intermittent reactivation does occur in normal hosts, and considerable evidence shows that T cells recognizing lytic γ HV68 antigens are continuously stimulated during latency, suggesting that lytic viral gene expression, and perhaps persistent replication at a level undetectable by current assays, does occur in normal hosts (47–53).

It is interesting that two genes that are important for efficient reactivation ex vivo (*v-cyclin* and *v-bcl-2*) are also important for persistent replication in an immunocompromised host. This strongly supports the hypothesis that persistent virus is derived from reactivation events rather than continued passage of infectious virus from one lytically infected cell to the next. In this model, persistent virus would derive from reactivation events with expansion of the reactivation-derived virus limited by components of the immune system. One such host factor is IFN- γ , which controls latency, persistence, and chronic disease due to infection with both the γ -herpesvirus γ HV68 (54; unpublished data) and the γ -herpesvirus murine cytomegalovirus (32, 38, 55). It is possible that effective control of chronic γ -herpesvirus infection would best be accomplished by simultaneous blockade of the function of genes critical for reactivation and persistent replication and enhancement of immune functions such as IFN- γ that are critical for controlling reactivation from latency and persistence.

We also thank members of the laboratories of H.W. Virgin, S.H. Speck, David Leib, and Lynda Morrison for constructive comments on this research. Helpful comments on the manuscript were made by Beth Levine, Scott A. Tibbetts, and Joy T. Loh.

H.W. Virgin was supported by grant RPG-97-134-01-MBC from the American Cancer Society and National Institutes of Health grants AI39616, CA74730, and HL60090. S.H. Speck was supported by National Institutes of Health grants CA43143, CA52004, CA58524, CA74730. L.F. van Dyk was supported by grant 5T32 AI 07163 from the National Institutes of Health.

Submitted: 31 October 2001

Revised: 2 January 2002

Accepted: 4 February 2002

References

1. Pipas, J.M., and A.J. Levine. 2001. Role of T antigen interactions with p53 in tumorigenesis. *Semin. Cancer Biol.* 11:23–30.
2. Jung, J.U., J.K. Choi, A. Ensser, and B. Biesinger. 1999. Herpesvirus saimiri as a model for gammaherpesvirus oncogenesis. *Semin. Cancer Biol.* 9:231–239.
3. Wolf, J.K., and P.T. Ramirez. 2001. The molecular biology of cervical cancer. *Cancer Invest.* 19:621–629.
4. Kao, W.H., S.L. Beaudenon, A.L. Talis, J.M. Huibregtse, and P.M. Howley. 2000. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. *J. Virol.* 74:6408–6417.
5. Virgin, H.W., P. Latreille, P. Wamsley, K. Hallsworth, K.E.

- Weck, A.J. Dal Canto, and S.H. Speck. 1997. Complete sequence and genomic analysis of murine gammaherpesvirus 68. *J. Virol.* 71:5894–5904.
6. Wang, G.H., T.L. Garvey, and J.I. Cohen. 1999. The murine gammaherpesvirus-68 M11 protein inhibits Fas- and TNF-induced apoptosis. *J. Gen. Virol.* 80:2737–2740.
 7. Bellows, D.S., B.N. Chau, P. Lee, Y. Lazebnik, W.H. Burns, and J.M. Hardwick. 2000. Antiapoptotic herpesvirus bcl-2 homologs escape caspase-mediated conversion to proapoptotic proteins. *J. Virol.* 74:5024–5031.
 8. Henderson, S., D. Huen, M. Rowe, C. Dawson, G. Johnson, and A. Rickinson. 1993. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. *Proc. Natl. Acad. Sci. USA.* 90:8479–8483.
 9. Sarid, R., T. Sato, R.A. Bohenzky, J.J. Russo, and Y. Chang. 1997. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. *Nat. Med.* 3:293–298.
 10. Nava, V.E., E.H. Cheng, M. Veliuona, S. Zou, R.J. Clem, M.L. Mayer, and J.M. Hardwick. 1997. *Herpesvirus saimiri* encodes a functional homolog of the human bcl-2 oncogene. *J. Virol.* 71:4118–4122.
 11. Brun, A., F. Rodriguez, J.M. Escibano, and C. Alonso. 1998. Functionality and cell anchorage dependence of the African swine fever virus gene A179L, a viral bcl-2 homolog, in insect cells. *J. Virol.* 72:10227–10233.
 12. Brun, A., C. Rivas, M. Esteban, J.M. Escibano, and C. Alonso. 1996. African swine fever virus gene A179L, a viral homologue of bcl-2, protects cells from programmed cell death. *Virology.* 225:227–230.
 13. Sundararajan, R., and E. White. 2001. E1B 19K blocks Bax oligomerization and tumor necrosis factor alpha-mediated apoptosis. *J. Virol.* 75:7506–7516.
 14. Perez, D., and E. White. 2000. TNF-alpha signals apoptosis through a bid-dependent conformational change in Bax that is inhibited by E1B 19K. *Mol. Cell.* 6:53–63.
 15. Han, J., D. Modha, and E. White. 1998. Interaction of E1B 19K with Bax is required to block Bax-induced loss of mitochondrial membrane potential and apoptosis. *Oncogene.* 17:2993–3005.
 16. Han, J., H.D. Wallen, G. Nunez, and E. White. 1998. E1B 19,000-molecular-weight protein interacts with and inhibits CED-4-dependent, FLICE-mediated apoptosis. *Mol. Cell Biol.* 18:6052–6062.
 17. Marchini, A., B. Tomkinson, J.I. Cohen, and E. Kieff. 1991. BHRF1, the Epstein-Barr virus gene with homology to bcl2, is dispensable for B-lymphocyte transformation and virus replication. *J. Virol.* 65:5991–6000.
 18. Van Dyk, L.F., H.W. Virgin, and S.H. Speck. 2000. The murine gammaherpesvirus 68 v-cyclin is a critical regulator of reactivation from latency. *J. Virol.* 74:7451–7461.
 19. Albrecht, J.-C., J. Nicholas, D. Biller, K.R. Cameron, B. Biesinger, C. Newman, S. Wittmann, M.A. Craxton, H. Coleman, B. Fleckenstein, and R.W. Honess. 1992. Primary structure of the herpesvirus saimiri genome. *J. Virol.* 66:5047–5058.
 20. Russo, J.J., R.A. Bohenzky, M.-C. Chien, J. Chen, M. Yan, D. Maddalena, J.P. Parry, D. Peruzzi, I.S. Edelman, Y. Chang, and P.S. Moore. 1996. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). *Proc. Natl. Acad. Sci. USA.* 93:14862–14867.
 21. Jung, J.U., M. Stager, and R.C. Desrosiers. 1994. Virus-encoded cyclin. *Mol. Cell. Biol.* 14:7235–7244.
 22. Nicholas, J., K.R. Cameron, and R.W. Honess. 1992. Herpesvirus saimiri encodes homologs of G protein-coupled receptors and cyclins. *Nature.* 355:362–365.
 23. Arvanitakis, L., N. Yaseen, and S. Sharma. 1995. Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta-1-mediated growth inhibition on EBV-positive B cells. *J. Immunol.* 155:1047–1056.
 24. Cannell, E.J., P.J. Farrell, and A.J. Sinclair. 1996. Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B-cells. *Oncogene.* 13:1413–1421.
 25. Sinclair, A.J., I. Palmero, A. Holder, G. Peters, and P.J. Farrell. 1995. Expression of cyclin D2 in Epstein-Barr virus positive Burkitt's lymphoma cell lines is related to methylation status of the gene. *J. Virol.* 69:1292–1295.
 26. Van Dyk, L.F., J.L. Hess, J.D. Katz, M. Jacoby, S.H. Speck, and H.W. Virgin. 1999. The murine gammaherpesvirus 68 v-cyclin is an oncogene that promotes cell cycle progression in primary lymphocytes. *J. Virol.* 73:5110–5122.
 27. Hoge, A.T., S.B. Hendrickson, and W.H. Burns. 2000. Murine gammaherpesvirus 68 cyclin D homologue is required for efficient reactivation from latency. *J. Virol.* 74:7016–7023.
 28. Weck, K.E., M.L. Barkon, L.I. Yoo, S.H. Speck, and H.W. Virgin. 1996. Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus 68. *J. Virol.* 70:6775–6780.
 29. Clambey, E.T., H.W. Virgin, and S.H. Speck. 2000. Disruption of the murine gammaherpesvirus 68 M1 open reading frame leads to enhanced reactivation from latency. *J. Virol.* 74:1973–1984.
 30. Muller, U., S. Steinhoff, L.F.L. Reis, S. Hemmi, J. Pavlovic, R.M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. *Science.* 264:1918–1921.
 31. Weck, K.E., S.S. Kim, H.W. Virgin, and S.H. Speck. 1999. Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells. *J. Virol.* 73:3273–3283.
 32. Weck, K.E., A.J. Dal Canto, J.D. Gould, A.K. O'Guin, K.A. Roth, J.E. Saffitz, S.H. Speck, and H.W. Virgin. 1997. Murine gammaherpesvirus 68 causes large vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus induced vascular disease. *Nat. Med.* 3:1346–1353.
 33. Dal Canto, A.J., H.W. Virgin, and S.H. Speck. 2000. Ongoing viral replication is required for gammaherpesvirus 68-induced vascular damage. *J. Virol.* 74:11304–11310.
 34. Weck, K.E., S.S. Kim, H.W. Virgin, and S.H. Speck. 1999. B cells regulate murine gammaherpesvirus 68 latency. *J. Virol.* 73:4651–4661.
 35. Bodaghi, B., T.R. Jones, D. Zipeto, C. Vita, L. Sun, L. Laurent, F. Arenzana-Seisdedos, J.L. Virelizier, and S. Michelson. 1998. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. *J. Exp. Med.* 188:855–866.
 36. Penfold, M.E., D.J. Dairaghi, G.M. Duke, N. Saederup, E.S. Mocarski, G.W. Kemble, and T.J. Schall. 1999. Cytomegalovirus encodes a potent alpha chemokine. *Proc. Natl. Acad. Sci. USA.* 96:9839–9844.
 37. Patterson, C.E., and T. Shenk. 1999. Human cytomegalovirus UL36 protein is dispensable for viral replication in cultured cells. *J. Virol.* 73:7126–7131.

38. Dutia, B.M., C.J. Clarke, D.J. Allen, and A.A. Nash. 1997. Pathological changes in the spleens of gamma interferon receptor-deficient mice infected with murine gammaherpesvirus: a role for CD8 T cells. *J. Virol.* 71:4278–4283.
39. Terry, L.A., J.P. Stewart, A.A. Nash, and J.K. Fazakerley. 2000. Murine gammaherpesvirus-68 infection of and persistence in the central nervous system. *J. Gen. Virol.* 81:2635–2643.
40. Sunil-Chandra, N.P., S. Efstathiou, and A.A. Nash. 1992. Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo. *J. Gen. Virol.* 73:3275–3279.
41. Flano, E., S.M. Husain, J.T. Sample, D.L. Woodland, and M.A. Blackman. 2000. Latent murine gamma-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages. *J. Immunol.* 165:1074–1081.
42. Virgin, H.W., R.M. Presti, X.-Y. Li, C. Liu, and S.H. Speck. 1999. Three distinct regions of the murine gammaherpesvirus 68 genome are transcriptionally active in latently infected mice. *J. Virol.* 73:2321–2332.
43. Ojala, P.M., M. Tiainen, P. Salven, T. Veikkola, E. Castanos-Velez, R. Sarid, P. Biberfeld, and T.P. Makela. 1999. Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6. *Cancer Res.* 59:4984–4989.
44. Derfuss, T., H. Fickenscher, M.S. Kraft, G. Henning, D. Lengenfelder, B. Fleckenstein, and E. Meisl. 1998. Antiapoptotic activity of the herpesvirus saimiri-encoded bcl-2 homolog: stabilization of mitochondria and inhibition of caspase-3-like activity. *J. Virol.* 72:5897–5904.
45. Davis, J.E., V.R. Sutton, M.J. Smyth, and J.A. Trapani. 2000. Dependence of granzyme B-mediated cell death on a pathway regulated by Bcl-2 or its viral homolog, BHRF1. *Cell Death Differ.* 7:973–983.
46. Kirshner, J.R., K. Staskus, A. Haase, M. Lagunoff, and D. Ganem. 1999. Expression of the open reading frame 74 (G-protein-coupled receptor) gene of Kaposi's sarcoma (KS)-associated herpesvirus: implications for KS pathogenesis. *J. Virol.* 73:6006–6014.
47. Simas, J.P., D. Swann, R. Bowden, and S. Efstathiou. 1999. Analysis of murine gammaherpesvirus-68 transcription during lytic and latent infection. *J. Gen. Virol.* 80:75–82.
48. Christensen, J.P., and P.C. Doherty. 1999. Quantitative analysis of the acute and long-term CD4(+) T-cell response to a persistent gammaherpesvirus. *J. Virol.* 73:4279–4283.
49. Hamilton-Easton, A.M., J.P. Christensen, and P.C. Doherty. 1999. Turnover of T cells in murine gammaherpesvirus 68-infected mice. *J. Virol.* 73:7866–7869.
50. Stevenson, P.G., G.T. Belz, J.D. Altman, and P.C. Doherty. 1999. Changing patterns of dominance in the CD8⁺ T cell response during acute and persistent murine gamma-herpesvirus infection. *Eur. J. Immunol.* 29:1059–1067.
51. Flano, E., D.L. Woodland, M.A. Blackman, and P.C. Doherty. 2001. Analysis of virus-specific CD4(+) T cells during long-term gammaherpesvirus infection. *J. Virol.* 75:7744–7748.
52. Belz, G.T., and P.C. Doherty. 2001. Virus-specific and bystander CD8⁺ T-cell proliferation in the acute and persistent phases of a gammaherpesvirus infection. *J. Virol.* 75:4435–4438.
53. Stevenson, P.G., and P.C. Doherty. 1998. Kinetic analysis of the specific host response to a murine gammaherpesvirus. *J. Virol.* 72:943–949.
54. Christensen, J.P., R.D. Cardin, K.C. Branum, and P.C. Doherty. 1999. CD4(+) T cell-mediated control of a gamma-herpesvirus in B cell-deficient mice is mediated by IFN-gamma. *Proc. Natl. Acad. Sci. USA.* 96:5135–5140.
55. Presti, R.M., J.L. Pollock, A.J. Dal Canto, A.K. O'Guin, and H.W. Virgin. 1998. Interferon-gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. *J. Exp. Med.* 188:577–588.